Transine Therapeutics is a private biotechnology company, headquartered in Cambridge-UK, focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. Transine® pioneering technology is expected to offer an entirely unique mechanism of action for currently hard-to-treat diseases by massively extending the druggable proteome, enabling it to address diseases which have been beyond the reach of small molecules, conventional biologics or gene therapies.